Report cover image

Global Amyloidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 190 Pages
SKU # APRC20552689

Description

Summary

According to APO Research, The global Amyloidosis Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Amyloidosis Therapeutics include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Amyloidosis Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Amyloidosis Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for Amyloidosis Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Amyloidosis Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Amyloidosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Amyloidosis Therapeutics sales, projected growth trends, production technology, application and end-user industry.

Amyloidosis Therapeutics Segment by Company

Pfizer Inc.
GlaxoSmithKline Plc
SOM Innovation Biotech SL
Prothena Corporation Plc
ProteoTech, Inc.
Onyx Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Celgene Corporation
Bsim2
Bellus Health Inc.
Arcturus Therapeutics, Inc
Alnylam Pharmaceuticals, Inc.
Amyloidosis Therapeutics Segment by Type

Canakinumab
CAEL-101
ALN-TTRsc02
ALN-ANG
AG-10
Others
Amyloidosis Therapeutics Segment by Application

ATTR Amyloidoses
AL Amyloidosis
AA Amyloidoses
Others
Amyloidosis Therapeutics Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Amyloidosis Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Amyloidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Amyloidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Amyloidosis Therapeutics Market Size, 2020 VS 2024 VS 2031
1.3 Global Amyloidosis Therapeutics Market Size Estimates and Forecasts (2020-2031)
1.4 Global Amyloidosis Therapeutics Sales Estimates and Forecasts (2020-2031)
1.5 Global Amyloidosis Therapeutics Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Amyloidosis Therapeutics Market Dynamics
2.1 Amyloidosis Therapeutics Industry Trends
2.2 Amyloidosis Therapeutics Industry Drivers
2.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
2.4 Amyloidosis Therapeutics Industry Restraints
3 Amyloidosis Therapeutics Market by Manufacturers
3.1 Global Amyloidosis Therapeutics Revenue by Manufacturers (2020-2025)
3.2 Global Amyloidosis Therapeutics Sales by Manufacturers (2020-2025)
3.3 Global Amyloidosis Therapeutics Average Sales Price by Manufacturers (2020-2025)
3.4 Global Amyloidosis Therapeutics Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Amyloidosis Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Amyloidosis Therapeutics Manufacturers, Product Type & Application
3.7 Global Amyloidosis Therapeutics Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Amyloidosis Therapeutics Market CR5 and HHI
3.8.2 Global Top 5 and 10 Amyloidosis Therapeutics Players Market Share by Revenue in 2024
3.8.3 2024 Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
4 Amyloidosis Therapeutics Market by Type
4.1 Amyloidosis Therapeutics Type Introduction
4.1.1 Canakinumab
4.1.2 CAEL-101
4.1.3 ALN-TTRsc02
4.1.4 ALN-ANG
4.1.5 AG-10
4.1.6 Others
4.2 Global Amyloidosis Therapeutics Sales by Type
4.2.1 Global Amyloidosis Therapeutics Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Amyloidosis Therapeutics Sales by Type (2020-2031)
4.2.3 Global Amyloidosis Therapeutics Sales Market Share by Type (2020-2031)
4.3 Global Amyloidosis Therapeutics Revenue by Type
4.3.1 Global Amyloidosis Therapeutics Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Amyloidosis Therapeutics Revenue by Type (2020-2031)
4.3.3 Global Amyloidosis Therapeutics Revenue Market Share by Type (2020-2031)
5 Amyloidosis Therapeutics Market by Application
5.1 Amyloidosis Therapeutics Application Introduction
5.1.1 ATTR Amyloidoses
5.1.2 AL Amyloidosis
5.1.3 AA Amyloidoses
5.1.4 Others
5.2 Global Amyloidosis Therapeutics Sales by Application
5.2.1 Global Amyloidosis Therapeutics Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Amyloidosis Therapeutics Sales by Application (2020-2031)
5.2.3 Global Amyloidosis Therapeutics Sales Market Share by Application (2020-2031)
5.3 Global Amyloidosis Therapeutics Revenue by Application
5.3.1 Global Amyloidosis Therapeutics Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Amyloidosis Therapeutics Revenue by Application (2020-2031)
5.3.3 Global Amyloidosis Therapeutics Revenue Market Share by Application (2020-2031)
6 Global Amyloidosis Therapeutics Sales by Region
6.1 Global Amyloidosis Therapeutics Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Amyloidosis Therapeutics Sales by Region (2020-2031)
6.2.1 Global Amyloidosis Therapeutics Sales by Region (2020-2025)
6.2.2 Global Amyloidosis Therapeutics Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Amyloidosis Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Amyloidosis Therapeutics Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Amyloidosis Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Amyloidosis Therapeutics Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Amyloidosis Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Amyloidosis Therapeutics Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Amyloidosis Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Amyloidosis Therapeutics Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Amyloidosis Therapeutics Revenue by Region
7.1 Global Amyloidosis Therapeutics Revenue by Region
7.1.1 Global Amyloidosis Therapeutics Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Amyloidosis Therapeutics Revenue by Region (2020-2025)
7.1.3 Global Amyloidosis Therapeutics Revenue by Region (2026-2031)
7.1.4 Global Amyloidosis Therapeutics Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Amyloidosis Therapeutics Revenue (2020-2031)
7.2.2 North America Amyloidosis Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Amyloidosis Therapeutics Revenue (2020-2031)
7.3.2 Europe Amyloidosis Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Amyloidosis Therapeutics Revenue (2020-2031)
7.4.2 Asia-Pacific Amyloidosis Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Amyloidosis Therapeutics Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Amyloidosis Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Pfizer Inc.
8.1.1 Pfizer Inc. Comapny Information
8.1.2 Pfizer Inc. Business Overview
8.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
8.1.5 Pfizer Inc. Recent Developments
8.2 GlaxoSmithKline Plc
8.2.1 GlaxoSmithKline Plc Comapny Information
8.2.2 GlaxoSmithKline Plc Business Overview
8.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
8.2.5 GlaxoSmithKline Plc Recent Developments
8.3 SOM Innovation Biotech SL
8.3.1 SOM Innovation Biotech SL Comapny Information
8.3.2 SOM Innovation Biotech SL Business Overview
8.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
8.3.5 SOM Innovation Biotech SL Recent Developments
8.4 Prothena Corporation Plc
8.4.1 Prothena Corporation Plc Comapny Information
8.4.2 Prothena Corporation Plc Business Overview
8.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
8.4.5 Prothena Corporation Plc Recent Developments
8.5 ProteoTech, Inc.
8.5.1 ProteoTech, Inc. Comapny Information
8.5.2 ProteoTech, Inc. Business Overview
8.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
8.5.5 ProteoTech, Inc. Recent Developments
8.6 Onyx Pharmaceuticals, Inc.
8.6.1 Onyx Pharmaceuticals, Inc. Comapny Information
8.6.2 Onyx Pharmaceuticals, Inc. Business Overview
8.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
8.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
8.7 Millennium Pharmaceuticals, Inc.
8.7.1 Millennium Pharmaceuticals, Inc. Comapny Information
8.7.2 Millennium Pharmaceuticals, Inc. Business Overview
8.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
8.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
8.8 Isis Pharmaceuticals, Inc.
8.8.1 Isis Pharmaceuticals, Inc. Comapny Information
8.8.2 Isis Pharmaceuticals, Inc. Business Overview
8.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
8.8.5 Isis Pharmaceuticals, Inc. Recent Developments
8.9 Celgene Corporation
8.9.1 Celgene Corporation Comapny Information
8.9.2 Celgene Corporation Business Overview
8.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
8.9.5 Celgene Corporation Recent Developments
8.10 Bsim2
8.10.1 Bsim2 Comapny Information
8.10.2 Bsim2 Business Overview
8.10.3 Bsim2 Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
8.10.5 Bsim2 Recent Developments
8.11 Bellus Health Inc.
8.11.1 Bellus Health Inc. Comapny Information
8.11.2 Bellus Health Inc. Business Overview
8.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
8.11.5 Bellus Health Inc. Recent Developments
8.12 Arcturus Therapeutics, Inc
8.12.1 Arcturus Therapeutics, Inc Comapny Information
8.12.2 Arcturus Therapeutics, Inc Business Overview
8.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
8.12.5 Arcturus Therapeutics, Inc Recent Developments
8.13 Alnylam Pharmaceuticals, Inc.
8.13.1 Alnylam Pharmaceuticals, Inc. Comapny Information
8.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
8.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
8.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Amyloidosis Therapeutics Value Chain Analysis
9.1.1 Amyloidosis Therapeutics Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Amyloidosis Therapeutics Production Mode & Process
9.2 Amyloidosis Therapeutics Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Amyloidosis Therapeutics Distributors
9.2.3 Amyloidosis Therapeutics Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.